Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver FitzGerald

Showing results (251-260 of 288) with videos related to

Pageof 29
Sort By:
Biomedicines|October 27, 2022
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic ArthritisRobert Gurke, Annika Bendes, John Bowes, et al.
Annals of the Rheumatic Diseases|April 30, 2015
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locusJohn Bowes, Sabine Loehr, Ashley Budu-Aggrey, et al.
Annals of the Rheumatic Diseases|August 20, 2017
Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasisJohn Bowes, James Ashcroft, Nick Dand, et al.
The Journal of Rheumatology|May 3, 2017
Proceedings of the GRAPPA 2016 RetreatDeepak R Jadon, Dafna D Gladman, Philip J Mease, et al.
The Journal of Rheumatology|February 3, 2017
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016Ana-Maria Orbai, Maarten de Wit, Philip J Mease, et al.
The Journal of Rheumatology|May 5, 2007
Consensus on a core set of domains for psoriatic arthritisDafna D Gladman, Philip J Mease, Vibeke Strand, et al.
Plos One|July 11, 2013
Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeansJoanna E Cobb, Darren Plant, Edward Flynn, et al.
The Journal of Investigative Dermatology|April 6, 2007
Filaggrin null alleles are not associated with psoriasisYiwei Zhao, Ana Terron-Kwiatkowski, Haihui Liao, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Pageof 29

Showing results (251-260 of 288) with videos related to

Sort By:
Pageof 29
Biomedicines|October 27, 2022
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic ArthritisRobert Gurke, Annika Bendes, John Bowes, et al.
Annals of the Rheumatic Diseases|April 30, 2015
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locusJohn Bowes, Sabine Loehr, Ashley Budu-Aggrey, et al.
Annals of the Rheumatic Diseases|August 20, 2017
Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasisJohn Bowes, James Ashcroft, Nick Dand, et al.
The Journal of Rheumatology|May 3, 2017
Proceedings of the GRAPPA 2016 RetreatDeepak R Jadon, Dafna D Gladman, Philip J Mease, et al.
The Journal of Rheumatology|February 3, 2017
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016Ana-Maria Orbai, Maarten de Wit, Philip J Mease, et al.
The Journal of Rheumatology|May 5, 2007
Consensus on a core set of domains for psoriatic arthritisDafna D Gladman, Philip J Mease, Vibeke Strand, et al.
Plos One|July 11, 2013
Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeansJoanna E Cobb, Darren Plant, Edward Flynn, et al.
The Journal of Investigative Dermatology|April 6, 2007
Filaggrin null alleles are not associated with psoriasisYiwei Zhao, Ana Terron-Kwiatkowski, Haihui Liao, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Pageof 29